Table 3 Clinicopathologic characteristics of breast cancers with HER2-positive results by 2013 guidelines, but reclassified as HER2 negative by 2018 ASCO/CAP guidelines

From: Implementation of the 2018 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2/neu Assessment by FISH in breast cancers: predicted impact in a single institutional cohort

Tumor characteristics

Value

Number of patients

70

Age (range [mean])

25–95 (57.7)

Tumors types (n [%])

 Invasive ductal carcinoma

52

 Invasive lobular carcinoma

2

 Mixed ductal and lobular

6

 Special types

2

 NA

8

Histologic grade (n [%])

 G1

8 (12.5)

 G2

30 (46.9)

 G3

26 (40.6)

 NA

6

Pathologic stage (n [%])

 T1

39 (60.9)

 T2

19 (29.7)

 T3

6 (9.4)

 NA

6

Lymph node status (n [%])

 Positive lymph nodes

28 (45.2)

 Negative lymph nodes

34 (54.8)

 NA

8

Hormone status (n [%])

 ER+

63 (90)

 ER–

7 (10)

 PR+

56 (80)

 PR–

14 (20)

HER2 IHC (n [%])

 Negative (0,1+)

26 (37.1)

 Equivocal (2+)

44 (62.9)

 Positive (3+)

0

  1. G grade, NA not available, T tumor stage
Back to article page